Smartlens Secures $5.2 Million in Bridge Funding, Marked for FDA Clearance and Market Launch Efforts

SUNNYVALE, Calif.—Smartlens, Inc., a clinical-stage ophthalmic technology company advancing next-generation glaucoma management devices, has announced the closing of an oversubscribed $5.2 million bridge round led by Ambit Health Ventures. The financing will be used to advance the FDA clearance process and prepare for an expedited market launch of the company’s miLens product following clearance, the announcement advised. The round also included continued participation from existing investors Graphene Ventures and Boutique Venture Partners, along with new investment from Harvard Business School Alumni Angels GNY and a group of eyecare providers.